NAFDAC DG advocates local manufacturing of drugs to achieve UHC

The National Agency for Food and Drug Administration and Control (NAFDAC) has only given its approval to  May and Baker, a Pharmaceutical Company, to produce more Chloroquine as a clinical trial for the cure of coronavirus.

NAFDAC’s Director-General {D-G}, Prof. Mojisola Adeyeye, said this in a statement made available to the News Agency of Nigeria (NAN) in Abuja on Saturday.

Also read:NAFDAC partners PCN in combating counterfeit drugs

The D-G said that the approval for more production of the drug to check the menace of coronavirus followed the recommendation by the United States’ National Agency for Food and Control.

She said that the trial was also necessary since coronavirus symptoms were similar to that of malaria; hence, the need to give Chloroquine a trial in the regard.

“NAFDAC has approved Chloroquine as a clinical trial for the treatment of coronavirus.

“Directive has been given to May and Baker (M and B) to manufacture the drug in case it will be needed on emergency in the country.’’

NAFDAC’s D-G said that part of the agency’s responsibilities was to ensure that Nigerians have access to safe and essential medicines.

She added in the statement that pharmaceutical companies with capacity for the production of Chloroquine should seek NAFDAC’s approval so as to make the drug available for public use.

The News Agency of Nigeria (NAN) reports that President Donald Trump of the United States of America had on Thursday, March 19, announced that the U.S. had approved the anti-malaria drug, Chloroquine, for use as a treatment against coronavirus

NAFDAC said in its statement that the World Health Organisation (WHO), however, was yet to announce and approve any treatment for coronavirus pandemic.

Vanguard

Disclaimer

Comments expressed here do not reflect the opinions of vanguard newspapers or any employee thereof.